MedTrace Logo

A Study of Anti-PD-1 (Pembrolizumab) Therapy in Metastatic Melanoma (ADAPTeM)

NCT02663258 · Status: WITHDRAWN · Phase: PHASE2 · Type: INTERVENTIONAL

Last updated 2017-08-01

No results posted yet for this study

Summary

Abbreviated Title: An explorative Phase II study of Anti-PD-1 (Pembrolizumab) in patients with advanced melanoma (ADAPTeM)

Trial Phase: Phase II

Clinical Indication: Stage III unresectable/stage IV metastatic melanoma

Trial Type: Exploratory Phase II trial

Route of administration: Intravenous Pembrolizumab, 200mg, 3weekly

Trial Blinding: Unblinded; open label Phase II study

Treatment Groups: All participants treated with Pembrolizumab, 200mg iv, 3weekly

Number of trial subjects: 40

Estimated duration of trial: 24 months

Duration of Participation: 24 months

Conditions

Interventions

DRUG

Pembrolizumab

Sponsors & Collaborators

Principal Investigators

  • James Larkin · Royal Marsden NHS Foundation Trust

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-01-31
Primary Completion
2017-07-19
Completion
2017-07-19

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02663258 on ClinicalTrials.gov